Biaxin, Biaxin XL Articles
Abbott file NDA for HIV associated use of Biaxin
5 June 1995
Modern Triple Therapy For H Pylori
8 May 1995
Klaricid Approved For HP Eradication In UK
13 March 1995
January Rx Trends In The USA
13 March 1995
Abbott Posts Good Performance In 1994
23 January 1995
Abbott Files For H pylori Eradication
9 January 1995
Glaxo Files For Ranitidine Bismuth Citrate Approval
2 January 1995
French Ban On Abbott Zeclar Campaign
5 December 1994
Increased R&D Impacts Profits At Dainippon
5 December 1994
Abbott's AIDS Drug In Phase I/II Studies
24 October 1994
Eradication Therapy For Helicobacter Pylori
10 October 1994
Glaxo's Pipeline Update As Expected
19 September 1994
Abbott Approvals In USA
12 September 1994
ASTA/MERCK AND ABBOTT COLLABORATION
4 July 1994
FIRST CLINICAL DATA FOR GLAXO'S GR122311X
6 June 1994
ZOTON OFFERS BENEFITS OVER H2S & OMEPRAZOLE
18 April 1994
US PRODUCT NEWS IN BRIEF
18 April 1994
FUTURE LOOKS ROSY FOR LOSEC H PYLORI COMBO
4 April 1994
CLARITHROMYCIN LAUNCHED IN FRANCE
7 March 1994
BIAXIN PUT FORWARD FOR ULCER THERAPY
14 February 1994
1993 A RECORD YEAR FOR ABBOTT
24 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
BIAXIN EFFECTIVE FOR OTITIS MEDIA
25 October 1993
ABBOTT'S HYTRIN GETS BPH APPROVAL IN USA
11 October 1993
ABBOTT CAN PRODUCE "RESPECTABLE EARNINGS GROWTH"
23 August 1993
ABBOTT POSTS INCREASES IN 2ND QTR
19 July 1993
BIAXIN ACCELERATED US APPROVAL
31 May 1993
ABBOTT'S BIAXIN UNDER REVIEW
10 May 1993
SPANISH FIRM ESTEVE INTERNATIONALIZES
10 May 1993
ABBOTT ACHIEVES RECORD SALES
19 April 1993
PFIZER CONSIDERS PRICE CUTS
29 March 1993
RECORD RESULTS AT ABBOTT FOR 1992
25 January 1993
NEW H PYLORI RECOMMENDATIONS
12 October 1992
ABBOTT FILES BIAXIN NDA IN USA
7 September 1992
ABBOTT WITHDRAWS TEMAFLOXACIN
15 June 1992
STOCK MARKET COMMENTARY: TOKYO
11 May 1992
ABBOTT 1st QTR NET EARNINGS LEAP 16%
13 April 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
